Guardant Health Says Jury Unanimously Rejected All Of Natera's Counterclaims And Awarded $292.5M To Company, Including $175.5M In Punitive Damages

Benzinga · 11/25 22:23

The jury found that Natera engaged in a deliberate campaign to mislead cancer clinicians about Guardant Reveal – Guardant Health's tissue-free minimal residual disease (MRD) test for early-stage colorectal cancer (CRC) – in favor of Signatera™, Natera's competing product.